The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough.

J. Smith (Manchester, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Morice (Cottingham, United Kingdom), S. Birring (London, United Kingdom), M. Kitt (Kenilworth, NJ, United States of America), M. Sher (Largo, FL, United States of America), A. Tershakovec (Kenilworth, NJ, United States of America), W. Wu (Kenilworth, NJ, United States of America), Z. Xu (Kenilworth, NJ, United States of America), D. Muccino (Kenilworth, NJ, United States of America)

Source: International Congress 2018 – Management of chronic cough and respiratory muscle dysfunction
Session: Management of chronic cough and respiratory muscle dysfunction
Session type: Thematic Poster
Number: 811
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Smith (Manchester, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Morice (Cottingham, United Kingdom), S. Birring (London, United Kingdom), M. Kitt (Kenilworth, NJ, United States of America), M. Sher (Largo, FL, United States of America), A. Tershakovec (Kenilworth, NJ, United States of America), W. Wu (Kenilworth, NJ, United States of America), Z. Xu (Kenilworth, NJ, United States of America), D. Muccino (Kenilworth, NJ, United States of America). The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough.. 811

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: